肿瘤微环境
免疫系统
免疫抑制
癌症研究
免疫疗法
癌症免疫疗法
腺苷
生物
免疫学
下调和上调
腺苷受体
免疫检查点
T细胞
化学
免疫耐受
转移
癌症
免疫
细胞毒性T细胞
CD8型
癌细胞
医学
受体
药理学
肿瘤进展
移植排斥反应
结直肠癌
脂质信号
腺苷受体拮抗剂
先天免疫系统
细胞生物学
炎症
作者
Rashi Singhal,Nina W. Zhang,Zheng Hong Lee,Hannah Noelle Bell,Prarthana Dalal,Sumeet A. Solanki,Wesley Huang,Ryan James Rebernick,Peter Sajjakulnukit,Himani Jasewicz,Roshan Kumar,Nikhil Kumar Kotla,Amanda K. Huber,Mallappa Anitha,Liliane Morath,Subhash B. Arya,Shogo Takahashi,Carlos Ichiro Kasano-Camones,Eileen Carpenter,Marina Pasca di Magliano
标识
DOI:10.1038/s41467-026-78771-8
摘要
As solid tumors progress, the tumor microenvironment becomes increasingly immunosuppressive, impairing cytotoxic T-cell activity and limiting the efficacy of immune checkpoint blockade. However, the mechanistic drivers of this immunosuppression remain poorly understood. Here, we identify a tumor-derived lipid–neutrophil–adenosine axis as a critical regulator of immune suppression in advanced colorectal cancer (CRC). We show that fatty acids enriched in tumor interstitial fluid reprogram neutrophils toward an immunosuppressive phenotype through PPARα activation, upregulation of CD39 and CD73, and adenosine generation, ultimately leading to T-cell suppression. AB928, a dual A2aR/A2bR adenosine receptor antagonist currently in clinical trials, restores T-cell proliferation, effector function, and tumor-killing capacity in vitro and in vivo. Importantly, AB928 synergizes with anti-PD-1 therapy to enhance survival in an immunotherapy-resistant autochthonous model of metastatic CRC. Thus, our findings define a metabolic immune evasion mechanism in the microenvironment and provide a rationale for targeting neutrophil-derived adenosine signaling to improve immunotherapy responses in CRC. Lipid accumulation in solid tumors supports tumor progression by promoting immune evasion. Yet the molecular basis of this lipid-mediated immunosuppression remains unclear. Here, using murine models of advanced colorectal cancer, the authors uncover a metabolic-immune axis whereby tumor-derived fatty acids activate neutrophil PPARα, resulting in adenosine generation and T cell suppression. Importantly, treatment with a dual adenosine receptor antagonist restores T cell-mediated antitumor immunity and synergizes with anti-PD-1 therapy to enhance animal survival.
科研通智能强力驱动
Strongly Powered by AbleSci AI